Stanford study determines cost-effectiveness of lung cancer diagnostic tools

May 05, 2003

STANFORD, Calif. - A promising imaging system called FDG-PET is a cost-effective way to diagnose lung cancer if used selectively, said researchers at the Stanford University Medical Center and Veterans Affairs Palo Alto Health Care System. The team investigated a number of diagnostic methods and found that the cost-effectiveness of each approach depends critically on a patient's risk of malignancy.

FDG-PET, which stands for positron emission tomography with 18-fluorodeoxyglucoseis, is an imaging test that can identify malignant tumors on the basis of their increased metabolic rate. Although expensive, the test has become increasingly popular in evaluating single nodules, or spots on the lung, that could be cancerous.

"FDG-PET is very helpful an in almost all circumstances can provide useful information and improve outcomes," said Michael Gould, MD, lead author of a paper appearing in the May 6 issue of the Annals of Internal Medicine. "It's an expensive test, but we found it can be a very good value when it's used selectively."

More than 150,000 single lung nodules are discovered in patients each year in the United States. Most of the small, round or egg-shaped lesions are discovered incidentally on chest X-rays; about 60 percent of all nodules are benign. If a patient is diagnosed with lung cancer - the leading cause of cancer death among men and women in the United States and other developed countries - the only cure is the removal of the tumor before it spreads.

Gould said management of lung nodules can be challenging because clinicians and patients must take into account the risks and benefits of each approach. In addition to FDG-PET, other diagnostic and management tools for lung cancer include computed tomography, or CT, an inexpensive test that provides cross-sectional images of the body and is commonly used to evaluate a nodule; needle biopsy; surgery (considered the diagnostic "gold standard"); and "watchful waiting," in which chest X-rays or CT scans are repeated every several months.

Each approach has disadvantages, said Gould. FDG-PET is more expensive than CT but not 100 percent accurate; CT does not reliably distinguish between malignant and benign nodules; biopsy is potentially risky and does not always reveal presence of cancer; surgery is not recommended for patients with benign lesions; and watchful waiting could delay diagnosis and treatment in cases of malignancy.

"For every month you wait and observe, the cancer could be growing," said Gould, an assistant professor of medicine at the School of Medicine. "The cancer could be curable in the beginning but then wind up spreading." Gould's study aimed to quantify the health effects and economic costs associated with each approach.

The researchers first used literature review and meta-analysis to estimate the accuracy and complications of each diagnostic tool. They then studied survival outcome from a large tumor registry and Medicare claims data to estimate long-term outcomes and costs associated with the approaches. The team went on to conduct separate cost-effectiveness analyses for populations of patients with low, intermediate and high risks of malignancy.

The results were expressed in terms of costs, quality-adjusted life-years and incremental cost-effectiveness ratios. The researchers found that FDG-PET is highly effective for lung nodule diagnosis, but is most cost-effective when CT results and the risk of cancer conflict with one another, for example when CT results indicate a possible malignancy in a low-risk patient or, less commonly, when CT suggests a benign diagnosis in a high-risk patient. Such an approach ensures that FDG-PET is used in cases in which the diagnosis is most in doubt.

Among the team's other findings: Gould recommends that clinicians rely on CT as the initial test for almost all patients and use FDG-PET selectively. "As clinicians, our obligations are to our patients, but we also have an obligation to use resources wisely," said Gould, who is now studying the cost-effectiveness of FDG-PET for lymph node staging. "By using expensive technology unnecessarily we're not fulfilling that responsibility."
-end-
Gould's collaborators on the study include Gillian D. Sanders, PhD, assistant professor of medicine; Paul G. Barnett, PhD, consulting associate professor of health research and policy; Chara E. Rydzak, former research assistant; Courtney C. Maclean, former research assistant; Mark B. McClellan, MD, PhD, associate professor of economics and of medicine; and Douglas K. Owens, MD, associate professor of medicine. The research was funded by a Career Development Award from the Department of Veterans Affairs' Health Services Research and Development Service and the VA Cooperative Studies Program.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

PRINT MEDIA CONTACTS: Michelle Brandt at 650-723-02372 (mbrandt@stanford.edu) and Amy Adams at 650-723-3900 (amyadams@stanford.edu)
BROADCAST MEDIA CONTACT: Neale Mulligan at 650-724-2454 (nealem@stanford.edu)

Stanford University Medical Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.